Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AbbVie's Tepkinly (epcoritamab) wins European Commission approval for relapsed or refractory follicular lymphoma based on Ph3 data
Antibody, cancer, bispecific antibody, follicular lymphoma, combination therapy, CD20 target - Read more

PharmaEssentia's BESREMi (ropeginterferon alfa-2b) receives Health Canada approval for polycythemia vera treatment
Protein therapy, cancer, interferon, polycythemia vera, myeloproliferative neoplasm, hematologic malignancy - Read more

Novo Nordisk, Vivani Medical partner on ultra long-acting semaglutide implant NPM-139 for chronic weight management
Licensing deal, metabolic disease, drug delivery, small molecule, implant technology - Read more

Boehringer Ingelheim licenses Prime Vector Technologies' ORFV platform for cancer vaccine development, undisclosed payments
Licensing deal, oncology, vaccine, viral vector, milestone payments - Read more

Biocytogen, Whitehawk Therapeutics partner to develop five bispecific ADC candidates, upfront and milestone payments undisclosed
Co-development, antibody-drug conjugate, drug discovery, bispecific antibody, milestone payments - Read more

Tanabe Pharma sells manufacturing unit and 17 drugs to Towa Pharmaceutical for undisclosed sum
Divestiture, manufacturing agreement, small molecule, cardiovascular, generics - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Kailera Therapeutics, Hengrui Pharma's (HRS-7535) Ph3 trials meet primary endpoints in obesity and type 2 diabetes
Small molecule, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes - Read more

Compass Pathways' COMP360 (psilocybin) demonstrates durable Ph3 response in treatment-resistant depression
Small molecule, neurological, psilocybin, treatment-resistant depression, psychedelic therapy - Read more

Vaxart's oral pill COVID-19 vaccine shows favorable 12-month safety profile in Ph2b sentinel cohort
Vaccine, infectious disease, oral vaccine, COVID-19, SARS-CoV-2, mRNA vaccine - Read more

Kalohexis files confidential IPO, developing melanocortin-based obesity and cancer cachexia treatments
Clinical-stage, obesity, cancer cachexia, peptide therapy, melanocortin system - Read more

Abivax raises $920M in equity offering, advancing ulcerative colitis drug toward FDA filing
Autoimmune, small molecule, ulcerative colitis, clinical-stage - Read more

Nuvation Bio raises $287.5M via convertible senior notes offering, oncology company greenshoe fully exercised
Oncology, small molecule, clinical-stage - Read more

Cyllene Therapeutics raises €33M ($37.8M) Series C, advancing DNA medicine toward pivotal bladder trial
Gene therapy, neurological, HSV vector, clinical-stage, rare disease - Read more

Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B in largest-ever deal, expanding into endocrine diseases
Small molecule, rare disease, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Bristol Myers Squibb's Krazati (adagrasib) fails Ph3 confirmatory trial in KRAS G12C-mutated metastatic colorectal cancer
Small molecule, cancer, KRAS G12C inhibitor, colorectal cancer, combination therapy, EGFR blocker - Read more

Regeneron Pharmaceuticals flags $127M in-process R&D charge to hit Q2 GAAP and non-GAAP earnings
Licensing agreement, financial, revenue impact - Read more

Novartis cuts 322 New Jersey employees in fourth round of layoffs, totaling 572 at East Hanover site
Workforce reduction, oncology, operational, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here